Amyotrophic Lateral Sclerosis Treatment Market Poised for High Growth Driven by Emergence of Novel Therapies

 The amyotrophic lateral sclerosis (ALS) treatment market consists of therapeutics used for treating ALS or Lou Gehrig's disease. ALS is a rare neurodegenerative disease that causes the death of neurons controlling voluntary muscles. This leads to weakness and wasting away of muscles. The currently available medications aim to manage symptoms of the disease and extend survival. However, emerging novel therapies targeting the underlying causes are expected to revolutionize ALS treatment landscape. The global ALS treatment market is estimated to be valued at US$ 885.01 Mn in 2031 and is expected to exhibit a CAGR of 4.6% over the forecast period 2024-2031.

Key Takeaways
Key players operating in the amyotrophic lateral sclerosis (ALS) treatment market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi, Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, ADVANZ PHARMA.

The key opportunities in the ALS treatment market include the emergence of novel therapeutics targeting underlying causes and slower progression of the disease. A number of promising drug candidates are currently under research that can offer more effective treatment options. Further, increasing awareness and supportive government initiatives are helping improve diagnosis and access to care.

Globally, major pharmaceutical companies are investing in R&D to expand their portfolios of ALS medications. Companies are also pursuing collaborations to fast-track drug development and commercialization. Regional expansions will help address the unmet medical needs of ALS patients more efficiently on a global scale.

Market Drivers
The emergence of novel therapies targeting the underlying pathophysiology of ALS is a key driver for market growth. A number of candidates under research aim at slowing motor neuron degeneration, reducing protein aggregations, restoring nerve function, and modifying disease progression. This is expected to revolutionize the treatment landscape.

Market Restrains
The high cost of developing novel therapies and lack of approved drugs for altering disease progression are major challenges in the ALS treatment market. Further, the rare disease status and limited understanding of pathogenesis also hinders faster drug discovery and approvals.

Segment Analysis
The amyotrophic lateral sclerosis treatment market is dominated by the riluzole sub segment owing to its efficacy and prolonged usage. Riluzole is a neuroprotective agent that works by reducing glutamate-induced neurotoxicity and prolongs survival by several months. It has been found to reduce neuronal degeneration and decrease inflammation and oxidative stress. Riluzole was the first drug approved by the FDA for the treatment of ALS in 1995 and remains the primary drug used for ALS treatment.

Global Analysis
North America dominates the amyotrophic lateral sclerosis treatment market owing to presence of major players, growing initiatives to spread awareness about ALS, and availability of advanced healthcare facilities in countries like United States and Canada. The region is estimated to account for more than 40% market share throughout the forecast period. Europe holds the second largest market position due to rising geriatric population, increasing research funding activities, and supportive government initiatives for orphan diseases. However, Asia Pacific is expected to grow at the fastest pace owing to improving healthcare infrastructure, rising disposable incomes, and growing focus of international players on emerging Asian countries.